Orlistat: its current status as an anti-obesity drug.

@article{Ballinger2002OrlistatIC,
  title={Orlistat: its current status as an anti-obesity drug.},
  author={Anne B Ballinger and Steven R. Peikin},
  journal={European journal of pharmacology},
  year={2002},
  volume={440 2-3},
  pages={109-17}
}
Orlistat is a non-centrally acting anti-obesity agent that acts locally in the gastrointestinal tract to inhibit lipase, an enzyme that is crucial for the digestion of long-chain triglycerides. At the recommended dose of 120 mg three times daily, orlistat inhibits dietary fat absorption by about 30%. Over a 1-year period, obese patients taking orlistat in combination with a hypocaloric diet show a reduction of 2-5 kg over the weight decrease with placebo. When continued for a second year in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 61 extracted citations

Similar Papers

Loading similar papers…